The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection

被引：3

作者：

Hong, Stacey ^{[1
,2
]}

Knight, Daniel R. ^{[1
]}

Riley, Thomas, V ^{[1
,2
,3
,4
]}

机构：

[1] Murdoch Univ, Med Mol & Forens Sci, Murdoch, WA 6105, Australia

[2] Univ Western Australia, Queen Elizabeth II Med Ctr, Sch Biomed Sci, Nedlands, WA 6009, Australia

[3] Edith Cowan Univ, Sch Med & Hlth Sci, Joondalup, WA 6027, Australia

[4] Queen Elizabeth II Med Ctr, PathWest Lab Med, Dept Microbiol, Nedlands, WA 6009, Australia

来源：

MICROBIOLOGY AUSTRALIA | 2019年 / 40卷 / 02期

关键词：

METRONIDAZOLE RESISTANCE; MULTIDRUG-RESISTANCE; CLINICAL STRAINS; EPIDEMIOLOGY; HEALTH; GENE; FIDAXOMICIN; VANCOMYCIN;

D O I：

10.1071/MA19022

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Clostridium difficile infection (CDI) of the gastrointestinal (GI) tract is a potentially life-threatening disease that has surpassed multi-drug-resistant Staphylococcus aureus as the commonest antimicrobial-resistant organism associated with healthcare(1). This obligate anaerobic spore-forming Gram-positive bacillus colonises the GI tract and its numbers increase after disruption of the commensal GI microbiota often induced by exposure to antimicrobial agents(2). Paradoxically, the disease that may follow its outgrowth necessitates further antimicrobial treatment. Already a major challenge to infection prevention and control strategies, there are indications that C. difficile is developing further resistance to currently used antimicrobial agents.

引用

页码：77 / 81

页数：5